Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma
Kite’s KTE-X19 under review in Europe
EMA has accepted an MAA for KTE-X19 from Kite, positioning the CAR T cell therapy from the Gilead Sciences Inc. (NASDAQ:GILD) unit to become the first CAR T cell therapy approved for mantle cell lymphoma in Europe. It is already under review by FDA.
Alkermes’ ALKS 3831 under FDA